NO20053185L - Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse. - Google Patents

Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse.

Info

Publication number
NO20053185L
NO20053185L NO20053185A NO20053185A NO20053185L NO 20053185 L NO20053185 L NO 20053185L NO 20053185 A NO20053185 A NO 20053185A NO 20053185 A NO20053185 A NO 20053185A NO 20053185 L NO20053185 L NO 20053185L
Authority
NO
Norway
Prior art keywords
treatment
hyperactivity disorder
attention
failure
attention failure
Prior art date
Application number
NO20053185A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053185D0 (no
Inventor
Jr Vincent Edward Groppi
Donn Gregory Wishka
Eric Jon Jacobsen
Jason Kenneth Myers
David Walter Piotrowski
Bruce Nelsen Rogers
Daniel Patrick Walker
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20053185D0 publication Critical patent/NO20053185D0/no
Publication of NO20053185L publication Critical patent/NO20053185L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20053185A 2002-12-11 2005-06-29 Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse. NO20053185L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43258602P 2002-12-11 2002-12-11
PCT/IB2003/005542 WO2004052461A1 (en) 2002-12-11 2003-11-28 Combination for the treatment of adhd

Publications (2)

Publication Number Publication Date
NO20053185D0 NO20053185D0 (no) 2005-06-29
NO20053185L true NO20053185L (no) 2005-08-17

Family

ID=32507968

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053185A NO20053185L (no) 2002-12-11 2005-06-29 Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse.

Country Status (23)

Country Link
US (1) US20050107425A1 (is)
EP (1) EP1572300A1 (is)
JP (1) JP2006510663A (is)
KR (1) KR20050085538A (is)
CN (1) CN1735441A (is)
AP (1) AP2005003336A0 (is)
AU (1) AU2003283656A1 (is)
BR (1) BR0317229A (is)
CA (1) CA2509142A1 (is)
CO (1) CO5700801A2 (is)
CR (1) CR7868A (is)
EA (1) EA200500783A1 (is)
EC (1) ECSP055852A (is)
HR (1) HRP20050522A2 (is)
IS (1) IS7858A (is)
MA (1) MA27606A1 (is)
MX (1) MXPA05006336A (is)
NO (1) NO20053185L (is)
OA (1) OA12969A (is)
PL (1) PL377552A1 (is)
TN (1) TNSN05158A1 (is)
WO (1) WO2004052461A1 (is)
ZA (1) ZA200504338B (is)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0310867D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
AU2005227324A1 (en) 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
US20100056600A1 (en) * 2007-03-28 2010-03-04 Soren Ebdrup 11beta-hsd1 active compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
NZ594937A (en) * 2008-02-19 2013-03-28 Adolor Corp Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
PL3029039T3 (pl) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu
WO2012015715A1 (en) 2010-07-27 2012-02-02 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
KR102629135B1 (ko) 2021-08-19 2024-01-29 단국대학교 천안캠퍼스 산학협력단 Kds2010을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
EP4389126A1 (en) 2021-08-20 2024-06-26 Dankook University Cheonan Campus Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating attention deficit/hyperactivity disorder
KR20230027862A (ko) 2021-08-20 2023-02-28 단국대학교 천안캠퍼스 산학협력단 주의력결핍 과잉행동장애의 진단을 위한 gat-3의 용도
KR102597711B1 (ko) 2021-08-20 2023-11-06 단국대학교 천안캠퍼스 산학협력단 Snap5114을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
CO5700801A2 (es) 2006-11-30
CR7868A (es) 2005-07-08
CN1735441A (zh) 2006-02-15
ECSP055852A (es) 2005-09-20
PL377552A1 (pl) 2006-02-06
MXPA05006336A (es) 2005-08-26
AP2005003336A0 (en) 2005-06-30
JP2006510663A (ja) 2006-03-30
EA200500783A1 (ru) 2005-12-29
MA27606A1 (fr) 2005-11-01
TNSN05158A1 (fr) 2007-05-14
NO20053185D0 (no) 2005-06-29
KR20050085538A (ko) 2005-08-29
EP1572300A1 (en) 2005-09-14
IS7858A (is) 2005-05-23
OA12969A (en) 2006-10-13
BR0317229A (pt) 2005-11-01
ZA200504338B (en) 2006-07-26
HRP20050522A2 (en) 2005-12-31
AU2003283656A1 (en) 2004-06-30
US20050107425A1 (en) 2005-05-19
WO2004052461A1 (en) 2004-06-24
CA2509142A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
NO20053185L (no) Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse.
NL301145I2 (nl) Tirbanibulin
PL372372A1 (en) Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
NO20100077L (no) Behandling med alfa7-selektive ligander
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
NO20052928L (no) Nye kjemiske forbindelser
NO20064124L (no) Anvendelse av metformin og orlistat for behandling eller forebygging av fedme
NO20054343L (no) Behandling av immunologiske lidelser ved anvendelse av agonister av interleukin-21/interleukin-21 reseptor
EP1638575A4 (en) TRANSDERMAL COMPOSITIONS AND METHODS FOR TREATING FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
EA199800620A1 (ru) Замещенные n-[(аминоиминометил или аминометил)фенил] пропиламиды
ATE459353T1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
NO20070914L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
DK1509618T3 (da) Autoimmune sygdomme og NADPH-oxidasedefekter
BRPI0515376A (pt) método para prevenir ou tratar diarréia em um mamìfero, composição útil na prevenção ou no tratamento de diarréia em um mamìfero, kit adequado para administrar um exopolissacarìdeo microbiano a um mamìfero, e, meio para comunicar informação
EP1896581A4 (en) MATERIALS, COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING IMMUNE-MEDIATED INFLAMMATORY DISORDERS
DK1575590T3 (da) Carbostyrilderivater og serotoningenoptagelsesinhibitorer til behandling af sindsstemningslidelser
ATE410235T1 (de) Behandlung von ballastwasser
EA199800152A1 (ru) Лечение синдрома дефицита внимания/гиперактивности
DE60223390D1 (de) Verfahren zum auffinden von verbindungen, die der vorsorge gegen cardiovasculäre krankheiten dienen
MX2009005400A (es) Metodo para el diagnostico y tratamiento del glioma.
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE423772T1 (de) Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
DE60109799D1 (de) Verwendung von quetiapin für aufmerksamkeitsmangel-hyperaktivitätsstörungen oder verhaltensstörungen